US-based biotechnology firm Amgen has placed a public cash offer to acquire all shares in Nuevolution, a Danish-based biotech firm that specializes in small molecule drug discovery. Nuevolution reported a LTM turnover of SEK 22.3m and LTM EBITDA of SEK -104m by March 2019.
ⓘ This story was originally featured in our daily Nordic M&A Newsletter - we publish some of the newsletter content with delay through our M&A Newsletter Library
. If you would like more insights on this deal or industry then send us an email at email@example.com